Aaron Kian Ti Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aaron Kian Ti Tong has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
David Chee Eng Ng
Singapore General Hospital, Singapore
4 shared publicationsSue Ping Thang
Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, 1 Outram Road, Singapore, 169608 Singapore
4 shared publicationsDavid Chee-Eng Ng
Singapore General Hospital
3 shared publicationsKelvin Siu Hoong Loke
Nuclear Medicine and Molecular Imaging
3 shared publications- Winnie Wing-Chuen Lam
Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore
3 shared publications Arvind Kumar Sinha
Department of Diagnostic Imaging, National University Hospital, Singapore
2 shared publications
Latest Publications
- Open Access
- 21 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3559-3568
Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging
A common yet underdiagnosed cause of secondary hypertension, primary aldosteronism (PA) is characterized by excess aldosterone production, causing hypertension with increased risk of cardio-renal-metabolic complications. Accurate and timely localization of the source of aldosterone excess is crucial for management, in the form of curative adrenalectomy for unilateral aldosterone-producing adenoma or medical management for bilateral adrenal hyperplasia. The current diagnostic algorithm involves adrenal vein sampling (AVS) as the current “gold standard” in determining lateralization of aldosterone secretion, but its technical challenges present significant barriers to timely diagnosis and treatment. Recent technological advancements have contributed to the evolution of molecular imaging modalities such as 11C-metomidate positron emission tomography-computed tomography (11C-MTO PET-CT). Improved molecular imaging modalities hold significant potential to complement existing diagnostic pathways and refine treatment strategies for PA. This review evaluates different case scenarios comparing the utility of AVS with 11C-MTO PET-CT, suggesting a practical approach for its interpretation and highlighting the clinical decision-making process.
- 21 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3559-3568
Open AccessApproach to the Patient With Primary Aldosteronism: Role of Molecular Imaging
A common yet underdiagnosed cause of secondary hypertension, primary aldosteronism (PA) is characterized by excess aldosterone production, causing hypertension with increased risk of cardio-renal-metabolic complications. Accurate and timely localization of the source of aldosterone excess is crucial for management, in the form of curative adrenalectomy for unilateral aldosterone-producing adenoma or medical management for bilateral adrenal hyperplasia. The current diagnostic algorithm involves adrenal vein sampling (AVS) as the current “gold standard” in determining lateralization of aldosterone secretion, but its technical challenges present significant barriers to timely diagnosis and treatment. Recent technological advancements have contributed to the evolution of molecular imaging modalities such as 11C-metomidate positron emission tomography-computed tomography (11C-MTO PET-CT). Improved molecular imaging modalities hold significant potential to complement existing diagnostic pathways and refine treatment strategies for PA. This review evaluates different case scenarios comparing the utility of AVS with 11C-MTO PET-CT, suggesting a practical approach for its interpretation and highlighting the clinical decision-making process.
- 6 January 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (2) , 177-184
Clinical impact of Yttrium-90 resin microsphere radioembolization-induced hepatic adverse events and associations with predictive dosimetry
Objective: Radioembolization-induced liver disease (REILD) is a potentially life-threatening complication that can develop after yttrium-90 (Y-90) radioembolization. Our study determined to find associations between liver toxicity and Y-90 dosimetry. Methods: We analyzed cases of REILD and isolated hyperbilirubinemia that developed after Y-90 resin microsphere radioembolization for hepatocellular carcinoma with a focus on dosimetric parameters. Results: Out of a cohort of 413 patients, 12 patients developed REILD, and 17 patients had grade 3 isolated hyperbilirubinemia. All patients in the REILD group were Barcelona-Clinic Liver Cancer (BCLC) stage C, with portal vein thrombosis (PVT) on baseline imaging, and albumin–bilirubin (ALBI) score of 2. More cases of REILD had bilobar radioembolization compared with unilobar treatment. The median absorbed dose to nontumorous liver was 33.0 and 31.8 Gy for REILD and isolated hyperbilirubinemia, respectively. The median overall survival (mOS) for the REILD group was 5.1 months [interquartile range (IQR): 3.4–8.6 months], while mOS for the isolated hyperbilirubinemia group was 4.3 months (IQR: 2.9–5.3 months). Comparing patients with BCLC stage C in the larger database, those who developed REILD had poorer overall survival outcomes. Conclusion: Our study observed severe liver toxicity at absorbed doses below the recommended dose thresholds to nontumorous liver. ALBI scores greater than or equal to 2 predicted for postprocedural liver toxicities. Further prospective research is suggested to ascertain a safe absorbed dose threshold, incorporating ALBI, PVT status, and bilobar involvement. Caution is warranted when performing bilobar Y-90 radioembolization in ALBI greater than or equal to 2 patients, even at standard doses.
- 6 January 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (2) , 177-184
Clinical impact of Yttrium-90 resin microsphere radioembolization-induced hepatic adverse events and associations with predictive dosimetry
Objective: Radioembolization-induced liver disease (REILD) is a potentially life-threatening complication that can develop after yttrium-90 (Y-90) radioembolization. Our study determined to find associations between liver toxicity and Y-90 dosimetry. Methods: We analyzed cases of REILD and isolated hyperbilirubinemia that developed after Y-90 resin microsphere radioembolization for hepatocellular carcinoma with a focus on dosimetric parameters. Results: Out of a cohort of 413 patients, 12 patients developed REILD, and 17 patients had grade 3 isolated hyperbilirubinemia. All patients in the REILD group were Barcelona-Clinic Liver Cancer (BCLC) stage C, with portal vein thrombosis (PVT) on baseline imaging, and albumin–bilirubin (ALBI) score of 2. More cases of REILD had bilobar radioembolization compared with unilobar treatment. The median absorbed dose to nontumorous liver was 33.0 and 31.8 Gy for REILD and isolated hyperbilirubinemia, respectively. The median overall survival (mOS) for the REILD group was 5.1 months [interquartile range (IQR): 3.4–8.6 months], while mOS for the isolated hyperbilirubinemia group was 4.3 months (IQR: 2.9–5.3 months). Comparing patients with BCLC stage C in the larger database, those who developed REILD had poorer overall survival outcomes. Conclusion: Our study observed severe liver toxicity at absorbed doses below the recommended dose thresholds to nontumorous liver. ALBI scores greater than or equal to 2 predicted for postprocedural liver toxicities. Further prospective research is suggested to ascertain a safe absorbed dose threshold, incorporating ALBI, PVT status, and bilobar involvement. Caution is warranted when performing bilobar Y-90 radioembolization in ALBI greater than or equal to 2 patients, even at standard doses.
- 18 June 2021
- Published by Springer Nature
- p. 139-151
Internal Radiotherapy Using Radionuclides
- Open Access
- 1 September 2020
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 50 (5) , 419-433
Molecular Imaging and Therapy of Liver Tumors
- 1 September 2020
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 50 (5) , 419-433
Open AccessMolecular Imaging and Therapy of Liver Tumors
- Open Access
- 1 May 2020
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 48 (2) , 98-101
Divide and Conquer: Strategies in Singapore to Manage a Nuclear Medicine Department During COVID-19
The Covid-19 outbreak was declared a Public Health Emergency of International Concern by the World Health Organisation (WHO) on 30 January 2020. Since then, the virus has spread to affect more countries worldwide. During this period, our nuclear medicine at Singapore General Hospital segregated our staff and patients either by time, space, or both, to minimise contact and prevent the spread of the virus. We also made necessary changes to clinical practices and enforced strict infection control measures. We share our personal experience in managing a nuclear medicine department during this epidemic.
- 1 May 2020
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 48 (2) , 98-101
Open AccessDivide and Conquer: Strategies in Singapore to Manage a Nuclear Medicine Department During COVID-19
The Covid-19 outbreak was declared a Public Health Emergency of International Concern by the World Health Organisation (WHO) on 30 January 2020. Since then, the virus has spread to affect more countries worldwide. During this period, our nuclear medicine at Singapore General Hospital segregated our staff and patients either by time, space, or both, to minimise contact and prevent the spread of the virus. We also made necessary changes to clinical practices and enforced strict infection control measures. We share our personal experience in managing a nuclear medicine department during this epidemic.
- 10 April 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (7) , 618-628
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer—a prospective pilot study in an Asian population
Objective: Metastatic castration-resistant prostate cancers are aggressive tumors with poor prognosis. Prostate-specific membrane antigen-targeted radionuclide therapy is a potential treatment for these patients. Here, we report our initial experience in Singapore. Methods: Twenty men (median age 70) with progressive disease were prospectively recruited. Prostate-specific membrane antigen and fluorodeoxyglucose-PET/computed tomography were performed to confirm high prostate-specific membrane antigen-expression. Up to four cycles of 177lutetium-prostate-specific membrane antigen-I&T at 6–8 weekly intervals were administered. Patients were restaged 3 months following treatment. Primary endpoints were prostate-specific antigen decline ≥50% and treatment-related toxicity. Additional endpoints included radiological and clinical response as well as progression-free survival and overall survival from first cycle. Results: Sixty-seven cycles were administered (median 4 cycles per patient, mean 6.5 GBq per cycle). Sixty five percent had ≥1 line of prior chemotherapy, 90% abiraterone, enzalutamide or both, and 30% radium-223 radionuclide therapy. All had bone metastases and 35% had visceral metastases. Prostate-specific antigen decline ≥50% was achieved in 50%. Grade 3–4 hematotoxicity was seen in up to 15%. Grade 3–4 non-hematotoxicity was not observed. Eleven patients had restaging scans 3 months post-treatment (5 = partial response, 6 = progressive disease). Fifty-seven percent (4/7) with bone pain had pain improvement. Median progression-free survival was 5.9 months and median overall survival 13.1 months. Patients with prostate-specific antigen decline ≥50% had longer progression-free survival and overall survival. Conclusion: 177Lutetium-prostate-specific membrane antigen-I&T therapy is effective with tolerable side effects in our local setting. Prostate-specific antigen decline ≥50% is associated with longer progression-free survival and overall survival.
- 10 April 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (7) , 618-628
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer—a prospective pilot study in an Asian population
Objective: Metastatic castration-resistant prostate cancers are aggressive tumors with poor prognosis. Prostate-specific membrane antigen-targeted radionuclide therapy is a potential treatment for these patients. Here, we report our initial experience in Singapore. Methods: Twenty men (median age 70) with progressive disease were prospectively recruited. Prostate-specific membrane antigen and fluorodeoxyglucose-PET/computed tomography were performed to confirm high prostate-specific membrane antigen-expression. Up to four cycles of 177lutetium-prostate-specific membrane antigen-I&T at 6–8 weekly intervals were administered. Patients were restaged 3 months following treatment. Primary endpoints were prostate-specific antigen decline ≥50% and treatment-related toxicity. Additional endpoints included radiological and clinical response as well as progression-free survival and overall survival from first cycle. Results: Sixty-seven cycles were administered (median 4 cycles per patient, mean 6.5 GBq per cycle). Sixty five percent had ≥1 line of prior chemotherapy, 90% abiraterone, enzalutamide or both, and 30% radium-223 radionuclide therapy. All had bone metastases and 35% had visceral metastases. Prostate-specific antigen decline ≥50% was achieved in 50%. Grade 3–4 hematotoxicity was seen in up to 15%. Grade 3–4 non-hematotoxicity was not observed. Eleven patients had restaging scans 3 months post-treatment (5 = partial response, 6 = progressive disease). Fifty-seven percent (4/7) with bone pain had pain improvement. Median progression-free survival was 5.9 months and median overall survival 13.1 months. Patients with prostate-specific antigen decline ≥50% had longer progression-free survival and overall survival. Conclusion: 177Lutetium-prostate-specific membrane antigen-I&T therapy is effective with tolerable side effects in our local setting. Prostate-specific antigen decline ≥50% is associated with longer progression-free survival and overall survival.
- Open Access
- 1 April 2020
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 4 (Supplement)
OR34-01 11C Metomidate PET-CT Identifies More Unilateral Primary Aldosteronism Than Adrenal Vein Sampling
Introduction. Adrenal vein sampling (AVS) is the current reference test to identify unilateral, surgically-curable primary aldosteronism (PA). However, AVS is invasive and technically difficult. Even in AVS-proven unilateral PA, up to 6% of patients with fail to have biochemical cure after surgery using the PASO criteria. 11C-Metomidate PET-CT offers a non-invasive alternative. We compared the accuracy of both PET-CT and AVS using post-surgery cure (PASO criteria) as the reference. Methods. This multi-centre prospective trial recruited 25 patients with confirmed PA, and all underwent CT, AVS, and PET-CT tests. Sequential AVS under ACTH-stimulation was done by an experienced interventionalist, and cortisol gradient of >5 was taken to be successful cannulation. Lateralization ratio >4 was consistent with unilateral PA. All results were reviewed at a multidisciplinary meeting to decide on the diagnosis (unilateral or bilateral PA) and management (secondary outcome). Primary outcome was biochemical cure using PASO criteria at 6 months post-surgery (ClinicalTrials.gov: NCTxxxxxxxx). Results. Recruitment for the study has been complete with 25 patients, 49.2 ± 9.5 yr, 14 females (56.0%). All 25 patients had successful AVS. 22 of 25 patients (88.0%) had unilateral PA, and 3 patients (12.0%) had bilateral PA. PET-CT identified unilateral PA in 18 of 22 patients (sensitivity 81.8%), while AVS identified unilateral PA in 15 of 22 patients (sensitivity 68.2%). In one patient, repeat AVS done simultaneously without ACTH-stimulation aided to identify unilateral PA, when initial AVS failed to do so. Other cases where AVS failed to identify unilateral PA were due to venous anomalies, and limitation of the lateralization cut-off of 4. 18 of 22 patients have undergone surgery, with 3 patients awaiting surgery, and 1 opting for medical treatment. Post-surgery, all patients had complete normalization of aldosterone-renin ratio, and hypokalemia (if present). 2 patients had bilateral PA on both PET-CT and AVS. 1 patient had discordant AVS and PET-CT results, with AVS lateralizing to right, and PET-CT to left. This patient was classified as bilateral PA and treated medically. Conclusion. This is the first study to demonstrate that 11C-Metomidate PET-CT may identify cases of unilateral PA not detected with AVS, using the stringent PASO criteria for post-operative biochemical cure.
- 1 April 2020
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 4 (Supplement)
Open AccessOR34-01 11C Metomidate PET-CT Identifies More Unilateral Primary Aldosteronism Than Adrenal Vein Sampling
Introduction. Adrenal vein sampling (AVS) is the current reference test to identify unilateral, surgically-curable primary aldosteronism (PA). However, AVS is invasive and technically difficult. Even in AVS-proven unilateral PA, up to 6% of patients with fail to have biochemical cure after surgery using the PASO criteria. 11C-Metomidate PET-CT offers a non-invasive alternative. We compared the accuracy of both PET-CT and AVS using post-surgery cure (PASO criteria) as the reference. Methods. This multi-centre prospective trial recruited 25 patients with confirmed PA, and all underwent CT, AVS, and PET-CT tests. Sequential AVS under ACTH-stimulation was done by an experienced interventionalist, and cortisol gradient of >5 was taken to be successful cannulation. Lateralization ratio >4 was consistent with unilateral PA. All results were reviewed at a multidisciplinary meeting to decide on the diagnosis (unilateral or bilateral PA) and management (secondary outcome). Primary outcome was biochemical cure using PASO criteria at 6 months post-surgery (ClinicalTrials.gov: NCTxxxxxxxx). Results. Recruitment for the study has been complete with 25 patients, 49.2 ± 9.5 yr, 14 females (56.0%). All 25 patients had successful AVS. 22 of 25 patients (88.0%) had unilateral PA, and 3 patients (12.0%) had bilateral PA. PET-CT identified unilateral PA in 18 of 22 patients (sensitivity 81.8%), while AVS identified unilateral PA in 15 of 22 patients (sensitivity 68.2%). In one patient, repeat AVS done simultaneously without ACTH-stimulation aided to identify unilateral PA, when initial AVS failed to do so. Other cases where AVS failed to identify unilateral PA were due to venous anomalies, and limitation of the lateralization cut-off of 4. 18 of 22 patients have undergone surgery, with 3 patients awaiting surgery, and 1 opting for medical treatment. Post-surgery, all patients had complete normalization of aldosterone-renin ratio, and hypokalemia (if present). 2 patients had bilateral PA on both PET-CT and AVS. 1 patient had discordant AVS and PET-CT results, with AVS lateralizing to right, and PET-CT to left. This patient was classified as bilateral PA and treated medically. Conclusion. This is the first study to demonstrate that 11C-Metomidate PET-CT may identify cases of unilateral PA not detected with AVS, using the stringent PASO criteria for post-operative biochemical cure.
- 15 June 2019
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 48 (6) , 181-187
High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves’ Disease
Introduction: Our study aimed to identify the factors associated with successful first-time radioactive iodine (RAI) treatment in patients with Graves' disease (GD). Materials and Methods: This is a retrospective study of patients with GD who were treated with RAL Treatment success was defined as onset of permanent hypothyroidism or euthyroidism after 1 dose of RAI at 1-year follow-up. Results: There were 388 GD patients who underwent RAI treatment between January 2014 and December 2015. Of these, 74% achieved treatment success. Median time to achieve permanent hypothyroidism was 2 months. Male gender, smoking, higher antithyroid drug dosage, lower thyroid stimulating hormone (TSH) level, large goitre size and TSH receptor antibody (TRAb) titre at time of RAI were significantly associated with treatment failure. Multivariate analysis showed that larger goitre size and higher TRAb titre were associated with lower first-time RAI success. Conclusion: Larger goitre size and higher TRAb titre predict lower success of RAI therapy in GD patients. Treatment decisions and strategies should be customised for patients who present with these characteristics.
- 15 June 2019
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 48 (6) , 181-187
High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves’ Disease
Introduction: Our study aimed to identify the factors associated with successful first-time radioactive iodine (RAI) treatment in patients with Graves' disease (GD). Materials and Methods: This is a retrospective study of patients with GD who were treated with RAL Treatment success was defined as onset of permanent hypothyroidism or euthyroidism after 1 dose of RAI at 1-year follow-up. Results: There were 388 GD patients who underwent RAI treatment between January 2014 and December 2015. Of these, 74% achieved treatment success. Median time to achieve permanent hypothyroidism was 2 months. Male gender, smoking, higher antithyroid drug dosage, lower thyroid stimulating hormone (TSH) level, large goitre size and TSH receptor antibody (TRAb) titre at time of RAI were significantly associated with treatment failure. Multivariate analysis showed that larger goitre size and higher TRAb titre were associated with lower first-time RAI success. Conclusion: Larger goitre size and higher TRAb titre predict lower success of RAI therapy in GD patients. Treatment decisions and strategies should be customised for patients who present with these characteristics.
- 25 January 2019
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 53 (2) , 96-101
Current Status and Growth of Nuclear Theranostics in Singapore
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
- 25 January 2019
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 53 (2) , 96-101
Current Status and Growth of Nuclear Theranostics in Singapore
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
- Open Access
- 1 January 2019
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 16 (1) , 157-+
68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
- 1 January 2019
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 16 (1) , 157-+
Open Access68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy